Literature DB >> 2702381

Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model.

R G Dale1.   

Abstract

By combining existing linear-quadratic equations relating to decaying-source therapy with an assumed tumour repopulation factor, it has been possible to devise a method for the radiobiological assessment of permanent implants. For calculation purposes there is a time after which an implant can no longer be considered effective in sterilizing tumour cells. This "effective" treatment time for a permanent implant can be approximately defined in terms of the radionuclide decay constant, the potential doubling time, the initial dose-rate and the value of alpha in the tumour alpha/beta ratio. The analytical technique has been applied to a specific intercomparison of commonly encountered implants using 125I and 198Au, and suggests that, even in the most favourable cases, the former radionuclide offers few radiobiological advantages. Although not specifically discussed here, the method can also be applied to the assessment of various forms of biologically targeted radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702381     DOI: 10.1259/0007-1285-62-735-241

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  24 in total

1.  Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.

Authors:  R W Howell; S M Goddu; D V Rao
Journal:  Med Phys       Date:  1998-01       Impact factor: 4.071

2.  Biological effects and equivalent doses in radiotherapy: A software solution.

Authors:  Cyril Voyant; Daniel Julian; Rudy Roustit; Katia Biffi; Céline Lantieri
Journal:  Rep Pract Oncol Radiother       Date:  2013-09-29

3.  Dosimetric effect of tissue heterogeneity for (125)I prostate implants.

Authors:  Susana Maria Oliveira; Nuno José Teixeira; Lisete Fernandes; Pedro Teles; Pedro Vaz
Journal:  Rep Pract Oncol Radiother       Date:  2014-04-16

4.  Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy.

Authors:  R B Wilder; G L DeNardo; S Sheri; J F Fowler; B W Wessels; S J DeNardo
Journal:  Eur J Nucl Med       Date:  1996-08

5.  Cellular Response to Exponentially Increasing and Decreasing Dose Rates: Implications for Treatment Planning in Targeted Radionuclide Therapy.

Authors:  Jay H Solanki; Thomas Tritt; Jordan B Pasternack; Julia J Kim; Calvin N Leung; Jason D Domogauer; Nicholas W Colangelo; Venkat R Narra; Roger W Howell
Journal:  Radiat Res       Date:  2017-05-25       Impact factor: 2.841

6.  The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers.

Authors:  Zhe Jay Chen; Kenneth Roberts; Roy Decker; Pradip Pathare; Sara Rockwell; Ravinder Nath
Journal:  Phys Med Biol       Date:  2011-07-19       Impact factor: 3.609

7.  The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model.

Authors:  Joseph J Grudzinski; Wolfgang Tomé; Jamey P Weichert; Robert Jeraj
Journal:  Phys Med Biol       Date:  2010-09-08       Impact factor: 3.609

8.  A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy.

Authors:  Robert F Hobbs; Todd McNutt; Sébastien Baechler; Bin He; Caroline E Esaias; Eric C Frey; David M Loeb; Richard L Wahl; Ori Shokek; George Sgouros
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-13       Impact factor: 7.038

9.  Radiobiological assessment of non-standard and novel radiotherapy treatments using the linear-quadratic model.

Authors:  R G Dale
Journal:  Med Biol Eng Comput       Date:  1993-01       Impact factor: 2.602

10.  Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry.

Authors:  Sébastien Baechler; Robert F Hobbs; Andrew R Prideaux; Richard L Wahl; George Sgouros
Journal:  Med Phys       Date:  2008-03       Impact factor: 4.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.